Read Why Did WHO Suspend UN Supply of Bharat Biotech's Covaxin COVID-19 Vaccine - Ocugen (NASDAQ:OCGN)

According to Reuters, the World Health Organization suspended the supply of Covaxin through UN agencies for the COVID-19 vaccine.
WHO said it would allow the manufacturer to improve its facilities and address issues found in a WHO post-emergency use listing (EUL) inspection of Bharat Biotech's manufacturing.
The details of what the inspection found remain slim, other than the biotech's manufacturing practices did not meet GMP standards.
Ocugen Inc OCGN is a partner to bring Covaxin to the U.S.
Reuters added that the WHO had asked countries that have received the vaccine to take "appropriate actions" but that the agency did not specify what that might be.
Also Read: FDA Denies Pediatric EUA To Ocugen For Bharat Biotech's COVID-19 Vaccine Covaxin.
However, the WHO clarified that there are no safety or efficacy issues with the product.
The biotech said that the company is "fully committed to implementing the facility improvements and upgrades to ensure that the production of Covaxin meets all global regulatory requirements."
The announcement comes just one day after Bharat Biotech said it would be scaling back production of the vaccine, citing decreased demand alongside a decrease in infections and hospitalized patients.
Price Action: OCGN shares are up 3.31% at $3.41 during the market session on the last check Monday.
Photo by torstensimon from Pixabay